Marker for diagnosis and prognosis of severe tuberculosis

By detecting the concentration of sPD-L1 in plasma, using flow cytometry or ELISA methods, the problem of lack of effective diagnosis of severe pulmonary tuberculosis and prognosis in the prior art is solved, and the accurate diagnosis of severe pulmonary tuberculosis and efficient prediction of the prognosis of tuberculosis is achieved. .

CN119001114APending Publication Date: 2024-11-22BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411116145.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art lacks effective markers for diagnosing severe tuberculosis and prognosis, which makes it difficult to diagnose and prognosis clinically and affects the therapeutic effect.

Method used

SPD-L1 in plasma was screened as a biomarker for diagnosing severe pulmonary tuberculosis and predicting the prognosis of tuberculosis. The concentration was detected by flow cytometry or ELISA method, and the patient was diagnosed with severe pulmonary tuberculosis or predicting the risk of death.

Benefits of technology

sPD-L1 significantly distinguished patients with severe tuberculosis from non-severe patients, predicting high prognosis of tuberculosis, with flow cytometry detection AUC value >0.7, and ELISA method detection AUC value >0.8, indicating that it has high efficacy in diagnosis and prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004993671280000011
    Figure HDA0004993671280000011
  • Figure HDA0004993671280000012
    Figure HDA0004993671280000012
  • Figure HDA0004993671280000021
    Figure HDA0004993671280000021
Patent Text Reader

Abstract

The invention provides a marker for diagnosis and prognosis of severe tuberculosis, the biomarker is sPD-L1, and when the concentration of sPD-L1 in a sample is detected by flow cytometry, the AUC value of a patient with severe tuberculosis and the AUC value gt for predicting the prognosis effect of tuberculosis are both diagnosed; 0.7, 0.7; when the concentration of sPD-L1 in a sample is detected by adopting an ELISA method, the AUC value of a severe pulmonary tuberculosis patient and the AUC value gt for predicting the pulmonary tuberculosis prognosis effect are both gt; the result shows that the biomarker obtained by screening has relatively high diagnosis efficiency on pulmonary tuberculosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a marker for diagnosing severe pulmonary tuberculosis and prognosis. Background Art

[0002] Tuberculosis (TB) is an infectious disease caused by bacteria of the Mycobacterium tuberculosis (Mtb) complex. The disease is primarily transmitted by inhalation of aerosols containing droplets of Mtb Bacilli. Although most people infected with M. tuberculosis are asymptomatic (latent tuberculosis infection, TBI), with mild or moderate TB, some TB patients develop severe disease. In patients with severe TB, fibrosis, cavitation, and necrosis can cause long-term and irreversible damage to lung tissue and function, potentially leading to respiratory failure and death. Currently, there is a lack of effective markers for the diagnosis and prognosis of severe pulmonary TB in clinical practice.

[0003] PD-L1, also known as CD274 and B7-H1, is the ligand of the important immunosuppressive co-stimulatory molecule PD-1. It is widely expressed in human immune cells or non-immune cells and exerts its corresponding functions by interacting with its receptor PD-1. PD-L1 is a member of the B7 family. Its soluble form, sPD-L1, is believed to be produced by hydrolysis of membrane-bound proteins by metalloproteinases (MMP / ADAM) or by differential shearing of mRNA. It is a functional soluble form of PD-L1 molecules on the cell surface cleaved by matrix metalloproteinases (Khan M, Zhao Z, Arooj S, et al. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol, 2020, 11: 587460.). It activates the PD-1 / PD-L1 negative regulatory pathway by interacting with cell surface receptors (such as mPD-1), inhibiting T cell activation, proliferation and cytokine production, and playing a certain role in maintaining immune tolerance (Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer, 2006, 119(2): 317–327). sPD-L1 plays an important role in many diseases such as tumors, innate immunity, and inflammation, and has certain significance for monitoring treatment and predicting death from severe illness. It is a potential biomarker. Studies have found that the serum sPD-L1 level in patients with newly diagnosed diffuse large B-cell lymphoma was significantly higher than that in the control group. Serum sPD-L1 is a predictor of the metabolic response of diffuse large B-cell lymphoma patients to immunochemotherapy (El-Ghammaz AMS, Gadallah HA, Kamal G, et al. Impact of serum soluble programmed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients. Clin Exp Med, 2018, 18(4): 505–512).The highly expressed sPD-L1 in the serum of patients with pulmonary tuberculosis may mediate the production of the mPD-1 / sPD-L1 negative signaling pathway by binding to the mPD-L1 on T lymphocytes, weakening the body's T cell immune response ability to resist and eliminate MTB, allowing MTB to escape the body's immune killing and causing the body to be in a state of persistent infection. sPD-L1 expression was also found to be significantly increased in the pleural effusion and peripheral blood of patients with tuberculous pleurisy (Pan Xue, Xing Yufei, Shi Minhua, et al. Expression and significance of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleurisy [J]. Chinese Medical Journal, 2014, 94(20): 1543-1546). Further determination of whether sPD-L1 is an effective biomarker for the diagnosis and prognosis of severe pulmonary tuberculosis is in line with current clinical testing needs. Summary of the invention

[0004] The present invention screens out a marker for diagnosing severe pulmonary tuberculosis and predicting the prognosis of pulmonary tuberculosis, the marker shows significant changes in the patient's plasma, and has a strong diagnostic efficacy for diagnosing severe pulmonary tuberculosis and predicting the prognosis of pulmonary tuberculosis. Based on this, the present invention is completed.

[0005] In a first aspect, the present invention provides a biomarker for diagnosing severe pulmonary tuberculosis, wherein the biomarker is sPD-L1.

[0006] Furthermore, the biomarkers are derived from whole blood, plasma or serum of the patient.

[0007] Furthermore, the concentration of sPD-L1 in the sample is detected by flow cytometry or ELISA method; when the concentration of sPD-L1 in the sample is detected by flow cytometry, when the concentration of sPD-L1 is >53.94pg / ml, the patient is judged to have severe pulmonary tuberculosis; when the concentration of sPD-L1 in the sample is detected by ELISA method, when the concentration of sPD-L1 is >511.7pg / ml, the patient is judged to have severe pulmonary tuberculosis.

[0008] Further, the tuberculosis is an infection caused by the presence of Mycobacterium tuberculosis.

[0009] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.

[0010] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, and extrapulmonary infection.

[0011] In a second aspect, the present invention provides an application of a biomarker in the preparation of a reagent for diagnosing severe pulmonary tuberculosis, wherein the biomarker is sPD-L1, and the reagent is a reagent containing sPD-L1 that can detect the content of sPD-L1 in a biological sample of a patient.

[0012] Furthermore, the biological sample is whole blood, plasma or serum of a patient.

[0013] Furthermore, the concentration of sPD-L1 in the biological sample is detected by flow cytometry or ELISA method; when the concentration of sPD-L1 in the biological sample is detected by flow cytometry, when the concentration of sPD-L1 is >53.94pg / ml, the patient is judged to have severe pulmonary tuberculosis; when the concentration of sPD-L1 in the biological sample is detected by ELISA method, when the concentration of sPD-L1 is >511.7pg / ml, the patient is judged to have severe pulmonary tuberculosis.

[0014] In a third aspect, the present invention provides a kit for diagnosing severe pulmonary tuberculosis, wherein the kit comprises the reagent as described in the second invention of the present invention.

[0015] Furthermore, the kit may be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

[0016] Furthermore, the diagnostic method of the kit includes one or more of a direct method, an indirect method, a double antibody sandwich method and / or a competitive method.

[0017] In a fourth aspect, the present invention provides a biomarker for predicting the prognosis of pulmonary tuberculosis, wherein the biomarker is sPD-L1.

[0018] Furthermore, the biomarkers are derived from whole blood, plasma or serum of the patient.

[0019] Furthermore, the concentration of sPD-L1 in the test sample is detected by flow cytometry or ELISA method; when the concentration of sPD-L1 is detected by flow cytometry, when the concentration of sPD-L1 is >67.41pg / ml, the patient is judged to be at risk of death; when the concentration of sPD-L1 is detected by ELISA method, when the concentration of sPD-L1 is >791.9pg / ml, the patient is judged to be at risk of death.

[0020] In a fifth aspect, the present invention provides an application of a biomarker in a reagent for predicting the prognosis of pulmonary tuberculosis, wherein the biomarker is sPD-L1.

[0021] Furthermore, the biomarkers are derived from whole blood, plasma or serum of the patient.

[0022] Furthermore, the concentration of sPD-L1 in the test sample is detected by flow cytometry or ELISA method; when the concentration of sPD-L1 is detected by flow cytometry, when the concentration of sPD-L1 is >67.41pg / ml, the patient is judged to be at risk of death; when the concentration of sPD-L1 is detected by ELISA method, when the concentration of sPD-L1 is >791.9pg / ml, the patient is judged to be at risk of death.

[0023] In a sixth aspect, the present invention provides a kit for the prognosis effect of pulmonary tuberculosis, wherein the kit comprises the reagent as described in the fifth aspect of the present invention.

[0024] Furthermore, the kit may be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

[0025] Beneficial Effects

[0026] The biomarker sPD-L1 screened by the present invention can significantly distinguish patients with severe pulmonary tuberculosis from patients with non-severe pulmonary tuberculosis and predict the prognosis of pulmonary tuberculosis. When the concentration of sPD-L1 in the sample was detected by flow cytometry, the AUC value for diagnosing patients with severe pulmonary tuberculosis and the AUC value for predicting the prognosis of pulmonary tuberculosis were both >0.7; when the concentration of sPD-L1 in the sample was detected by ELISA, the AUC value for diagnosing patients with severe pulmonary tuberculosis and the AUC value for predicting the prognosis of pulmonary tuberculosis were both >0.8, indicating that the biomarker screened by the present invention has a high diagnostic efficacy for pulmonary tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The levels of sPD-L1 in plasma of healthy subjects (HC), non-severe pulmonary tuberculosis (Non-SE), and severe pulmonary tuberculosis (SE) were measured by flow cytometry;

[0028] Figure 2 ROC curve analysis of sPD-L1 in judging severe pulmonary tuberculosis by flow cytometry;

[0029] Figure 3 The level of sPD-L1 in plasma of surviving and non-surviving pulmonary tuberculosis was measured by flow cytometry;

[0030] Figure 4 ROC curve analysis for predicting death from pulmonary tuberculosis using flow cytometry sPD-L1

[0031] Figure 5 The levels of sPD-L1 in the plasma of healthy subjects, non-severe pulmonary tuberculosis patients, and severe pulmonary tuberculosis patients were measured by ELISA;

[0032] Figure 6ROC curve analysis of ELISA sPD-L1 in judging severe pulmonary tuberculosis;

[0033] Figure 7 The level of sPD-L1 in the plasma of surviving and non-surviving pulmonary tuberculosis patients was measured by ELISA;

[0034] Figure 8 ROC curve analysis of ELISA sPD-L1 in predicting death from pulmonary tuberculosis DETAILED DESCRIPTION

[0035] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0036] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0037] The "IGRA test" described in the present invention is an interferon gamma release assay, which uses the ELISA / ELISPOT (enzyme-linked immunosorbent assay / enzyme-linked immunospot) method to quantitatively detect the level of gamma interferon released by whole blood / peripheral blood mononuclear cells under the stimulation of Mycobacterium tuberculosis-specific antigens, and is used to screen for latent infection with Mycobacterium tuberculosis and diagnose tuberculosis.

[0038] Example 1 Screening of sPD-L1 for determining the severity of pulmonary tuberculosis and predicting prognosis

[0039] 1. Obtaining plasma samples

[0040] Plasma samples of subjects were from 10 healthy controls, 34 patients with non-severe pulmonary tuberculosis and 44 patients with severe pulmonary tuberculosis.

[0041] Healthy controls: aged ≥18 years; no clinical symptoms of tuberculosis; negative IGRA test; no lung lesions found in chest X-ray or CT; no other serious medical history.

[0042] Non-severe pulmonary tuberculosis: age ≥ 18 years; clinical symptoms of tuberculosis; lung lesions found on chest X-ray or CT, but the extent of lung lesions does not reach the level of severe pulmonary tuberculosis.

[0043] Severe pulmonary tuberculosis: active pulmonary tuberculosis patients aged ≥18 years, with unilateral dense lung lesions ≥1 / 3 of the lung field on one side, or bilateral lesions involving ≥1 / 2 of the whole lung, or cavity diameter >4cm, or with large pleural effusion, and serum CRP ≥75mg / L and PO2<80mmHg without oxygen inhalation or oxygenation index <300 with oxygen inhalation.

[0044] Exclusion criteria: patients receiving immunosuppressive drugs or hormone therapy; patients with autoimmune diseases; patients with viral hepatitis; patients with incomplete clinical data, patients transferred to other hospitals or patients who gave up the treatment; patients with cancer and active infection.

[0045] 2. Detection of sPD-L1 concentration in plasma samples by flow cytometry

[0046] (1) Sample storage: plasma is packaged and frozen;

[0047] (2) Detection of sPD-L1 concentration in plasma using flow cytometric microsphere immunoassay system

[0048] 1) Prepare the standard: dilute according to the kit instructions;

[0049] 2) Prepare buffer solution;

[0050] 3) Add microsphere-antibody mixture;

[0051] 4) Add standard or sample to be tested, mix well and incubate;

[0052] 5) Add SA-PE and incubate;

[0053] 6) Add buffer, vortex, centrifuge, and discard the supernatant;

[0054] 7) Repeat step 6.

[0055] 8) Add buffer, mix well and wait for detection.

[0056] 3. Experimental results

[0057] 3.1.sPD-L1 is used to determine the severity of pulmonary tuberculosis

[0058] The level of sPD-L1 in patients with severe pulmonary tuberculosis was significantly higher than that in patients with non-severe pulmonary tuberculosis (see Figure 1 ); According to the ROC curve, when the concentration of sPD-L1 in judging patients with severe pulmonary tuberculosis was 53.94 pg / ml, the area under the curve was 0.7533 (95% CI = 0.6468-0.8599); the sensitivity was 59.09% and the specificity was 82.35% (see Figure 2 ).

[0059] 3.2. sPD-L1 for predicting the prognosis of pulmonary tuberculosis

[0060] The level of sPD-L1 in non-surviving patients was significantly higher than that in surviving patients (see Figure 3 ); According to the ROC curve, when the concentration of sPD-L1 for predicting death from pulmonary tuberculosis was 67.41 pg / ml, the area under the curve was 0.7054 (95% CI = 0.5647-0.8460); the sensitivity was 64.29% and the specificity was 73.44% (see Figure 4 ).

[0061] Example 2 Validation of sPD-L1 for determining the severity of pulmonary tuberculosis and predicting prognosis

[0062] 1. Obtaining plasma samples

[0063] Plasma samples of subjects: from 79 healthy controls, 80 non-severe pulmonary tuberculosis patients and 60 severe pulmonary tuberculosis patients. The patient inclusion criteria and grouping were the same as those in Example 1.

[0064] 2. ELISA method to detect the concentration of sPD-L1 in plasma samples

[0065] (1) Antibody coating: Add coating solution to sPD-L1 monoclonal antibody and mix well, then add 2 μg / ml monoclonal antibody to the well plate.

[0066] (2) Blocking: Prepare blocking solution; after washing the plate, add blocking solution and incubate.

[0067] (3) Sample addition

[0068] ① Preparation of standard products:

[0069] Standard concentrations: 10 ng / ml, 1 ng / ml, 100 pg / ml, 50 pg / ml, 10 pg / ml, 5 pg / ml, 1 pg / ml, blank control (blocking solution).

[0070] ②Test sample: add 100ul of test plasma to each well;

[0071] ③Incubation;

[0072] ④Wash the board.

[0073] (4) Detection of antibodies

[0074] ① Prepare biotin-labeled antibody diluent: working concentration 2ug / ml;

[0075] ② Add detection antibody and incubate;

[0076] ③Wash the board.

[0077] (5) Avidin: Add avidin antibody, incubate, and wash the plate.

[0078] (6) Color development and reading: Add color developing solution and incubate for about 30 minutes; add stop solution and detect absorbance.

[0079] 3. Experimental results

[0080] 3.1.sPD-L1 is used to determine the severity of pulmonary tuberculosis

[0081] The level of sPD-L1 in patients with severe pulmonary tuberculosis was significantly higher than that in patients with non-severe pulmonary tuberculosis (see Figure 5 ); According to the ROC curve, when the concentration of sPD-L1 in judging patients with severe pulmonary tuberculosis was 511.7pg / ml, the area under the curve was 0.8050 (95%CI=0.7308-0.8808); the sensitivity was 71.67% and the specificity was 80.00% (see Figure 6 ).

[0082] 3.2. sPD-L1 for predicting the prognosis of pulmonary tuberculosis

[0083] The level of sPD-L1 in non-surviving patients was significantly higher than that in surviving patients (see Figure 7 ); According to the ROC curve, when the concentration of sPD-L1 for predicting tuberculosis death was 791.9 pg / ml, the area under the curve was 0.8392 (95% CI = 0.7409-0.9375); the sensitivity was 66.67% and the specificity was 82.81% (see Figure 8 ).

[0084] The results verified the diagnostic efficacy of sPD-L1 in determining the severity of pulmonary tuberculosis and predicting the prognosis of pulmonary tuberculosis, and confirmed its feasibility in actual clinical diagnosis.

Claims

1. A biomarker for diagnosing severe pulmonary tuberculosis, wherein the biomarker is sPD-L1.

2. Use of a biomarker in the preparation of a reagent for diagnosing severe pulmonary tuberculosis, wherein the biomarker is the sPD-L1 as described in claim 1, and the reagent is a reagent that can detect the content of sPD-L1 in a patient's biological sample.

3. A kit for diagnosing severe pulmonary tuberculosis, comprising the reagent as claimed in claim 2.

4. The marker according to claim 1, wherein the concentration of sPD-L1 in the sample is detected by flow cytometry or ELISA; when the concentration of sPD-L1 in the sample is detected by flow cytometry, when the concentration of sPD-L1 is >53.94 pg / ml, the patient is judged to have severe pulmonary tuberculosis; when the concentration of sPD-L1 in the sample is detected by ELISA, when the concentration of sPD-L1 is >511.7 pg / ml, the patient is judged to have severe pulmonary tuberculosis.

5. A biomarker for predicting the prognosis of pulmonary tuberculosis, wherein the biomarker is sPD-L1.

6. Use of a biomarker in a reagent for predicting the prognosis of pulmonary tuberculosis, wherein the biomarker is the sPD-L1 according to claim 5, and the reagent is a reagent containing a substance capable of detecting the content of sPD-L1 in a biological sample of a patient.

7. A kit for evaluating the prognosis of pulmonary tuberculosis, comprising the reagent according to claim 6.

8. The marker according to claim 5, wherein the concentration of sPD-L1 in the sample is detected by flow cytometry or ELISA; when the concentration of sPD-L1 is detected by flow cytometry, when the concentration of sPD-L1 is >67.41 pg / ml, the patient is judged to have a risk of death; when the concentration of sPD-L1 is detected by ELISA, when the concentration of sPD-L1 is >791.9 pg / ml, the patient is judged to have a risk of death.

9. The biomarker according to claim 1 or 5 is derived from whole blood, plasma or serum of a patient.

Citation Information

Patent Citations

  • Method for assisting determination of efficacy of immune checkpoint inhibitor

    US20210003579A1